Riskpilot← Back to searchSign inGet full accessCanacyl AB
ABActiveOrg 5594021213Svalvägen 9Research and experimental development on natural sciences and engineering · NACE 7210Est. 20220 employees
Revenue 2024
SEK 0
EBITDA margin
—
+78% vs 2023
Equity ratio
69.3%
Financial strength
Net profit 2024
SEK -10K
+78% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -10K | +78% |
| Net profit | SEK -10K | +78% |
| Total assets | SEK 141K | -6% |
| Equity | SEK 98K | -9% |
| Employees | 0 | — |
Legal name
Canacyl AB
Org number
5594021213
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
20 oktober 2022
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av verkställande direktören avseende löpande förvaltningsåtgärder trots att styrelsen inte är behörig. Styrelsen ska bestå av 3 styrelseledamöter och 0 styrelsesuppleanter. Registrerad behörig styrelse saknas. Därför saknas också uppgift om firmateckningsrätten. Registrerad styrelseordförande saknas.
Company purpose
Föremålet för bolagets verksamhet ät att bedriva forskning och utveckling av läkemedel och därmed förenlig verksamhet.
Address
Svalvägen 9
Email
andersbjoerk@telia.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2023 | 2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Staff expenses | — | — |
| EBITDA | −43 | −10 |
| Depreciation & amort. | — | — |
| EBIT | −43 | −10 |
| Net financials | — | −0 |
| Profit before tax | −43 | −10 |
| Tax | — | — |
| Net profit | −43 | −10 |
| Item | 2023 | 2024 |
|---|---|---|
| Total assets | 149 | 141 |
| Equity | 107 | 98 |
| Long-term debt | — | — |
| Short-term debt | 42 | 43 |
| Total debt | 42 | 43 |
EBITDA margin
-952200.0%
This company
15.8%
Market median
-6026682% vs market
20232024
Equity ratio
69.3%
This company
38.2%
Market median
+81% vs market
20232024
Return on equity
-9.7%
This company
18.4%
Market median
-153% vs market
20232024
Net profit margin
-952400.0%
This company
8.1%
Market median
-11758125% vs market
20232024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20232024
Debt / equity
0.44×
This company
0.62×
Market median
+29% vs market
20232024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-10-20 – 2023-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AK Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Canacyl AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Karl Konrad Björk | Chief Executive Officer | 0 companies |
| M H Charlotte Wiberg Larsson | Chairman | 0 companies |
| Bo Torsten Nilsson | Board of Directors | 0 companies |
| Derek Gregory Batcheller | Board of Directors | 0 companies |
| Derek Gregory Batcheller | Board of Directors | 0 companies |
| Mats Joel Wiktor | Chairman | 0 companies |
| Peter Jonas Michael Carlborg | Deputy Board Member | 0 companies |
| Bo Torsten Patrik Nilsson | Deputy Board Member | 0 companies |